Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B. 1994

M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
First Department of Internal Medicine, Gifu University School of Medicine, Japan.

OBJECTIVE Staphylococcal enterotoxin B (SEB) acts as a superantigen binding to class II major histocompatibility complex proteins, and this complex stimulates T cells. The aim of this study was to investigate the pathogenic effects of SEB on hepatic injury and lethal shock in mice. METHODS SEB was administered to D-galactosamine (GalN)-sensitized mice, and the degree of liver injury and levels of circulating cytokines were determined. In vitro cytokine production in response to SEB was also investigated. RESULTS Intraperitoneal administration of SEB (50 micrograms) caused lethal shock (50% mortality) associated with massive hepatic necrosis in GalN-sensitized mice, with no mortality on injection of up to 100 micrograms SEB alone. Within 2 hours after injection of SEB, serum tumor necrosis factor alpha (TNF-alpha) levels reached a peak, followed by high levels of serum interferon-gamma (IFN-gamma) up to 10 hours after injection. Passive immunization with anti-TNF-alpha/beta-neutralizing monoclonal antibody (mAb) protected GalN-sensitized mice from the lethal effects of SEB, with less protection with anti-IFN-gamma-neutralizing mAb. SEB induced the production of TNF-alpha and IFN-gamma in a dose-dependent manner from splenic mononuclear cells in vitro. CONCLUSIONS The results show that SEB contributes to lethal shock associated with severe hepatic injury in GalN-sensitized mice and suggest that TNF-alpha and IFN-gamma produced in response to SEB may be mediators of the lethal toxicity and hepatotoxicity of SEB.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D004768 Enterotoxins Substances that are toxic to the intestinal tract causing vomiting, diarrhea, etc.; most common enterotoxins are produced by bacteria. Staphylococcal Enterotoxin,Enterotoxin,Staphylococcal Enterotoxins,Enterotoxin, Staphylococcal,Enterotoxins, Staphylococcal
D005688 Galactosamine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D012769 Shock A pathological condition manifested by failure to perfuse or oxygenate vital organs. Circulatory Collapse,Circulatory Failure,Hypovolemic Shock,Collapse, Circulatory,Failure, Circulatory,Shock, Hypovolemic

Related Publications

M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
December 1995, Biochemical and biophysical research communications,
M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
November 1993, Infection and immunity,
M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
November 1999, Journal of hepatology,
M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
January 1992, The Journal of experimental medicine,
M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
January 2006, Antimicrobial agents and chemotherapy,
M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
January 2002, Journal of endotoxin research,
M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
September 1996, Gastroenterology,
M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
September 2012, Toxins,
M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
January 2001, Microbiology and immunology,
M Nagaki, and Y Muto, and H Ohnishi, and S Yasuda, and K Sano, and T Naito, and T Maeda, and T Yamada, and H Moriwaki
January 2003, Toxicologic pathology,
Copied contents to your clipboard!